MENU
REPL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Replimune Group (REPL) Ownership - Who owns Replimune Group?
Replimune Group Inc is a clinical-stage biotechnology company... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
284
Web
https://www.replimune.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
337.98M
P/E Ratio
N/A
Total Cash
403.34M
Projected Growth
N/A
Total Debt
76.33M
Revenue
N/A
Risk (Beta)
0.81
Dividend Yield
N/A
Total Cash/Share
5.17
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
REPL
Capitalization
338M
P/E Ratio
N/A
Risk (Beta)
0.81
Dividend Yield
N/A
Total Cash
403M
Total Cash/Share
5.17
Total Debt
76.3M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
337M
P/B Ratio
1.00
Cash Flow
N/A
Earnings
-3.24
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
78K
Current Ratio
6.94
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-268.18M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-55.79
Shares Held By Institutions
1.04B
Shares Outstanding - Current
78.1M
Total Liabilities
133M
Total Volume MTD
N/A
Value
1
Gain YTD
-64.244
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. REPL showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Unicorn Park Drive
Phone
+1 781 222-9600
Employees
284
Web
https://www.replimune.com